12:00 AM
 | 
Mar 18, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Status

N6022: Phase Ib/IIa started

N30 began a double-blind, placebo-controlled, U.S. Phase Ib/IIa trial to evaluate ascending doses of IV N6022 in about 67 patients with CF who are homozygous for the delta...

Read the full 116 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >